Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $469,100.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $93.82, for a total value of $469,100.00. Following the sale, the chief financial officer owned 44,788 shares of the company’s stock, valued at $4,202,010.16. The trade was a 10.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 16th, Eric Bjerkholt sold 7,287 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $91.98, for a total value of $670,258.26.

Mirum Pharmaceuticals Price Performance

Shares of MIRM traded up $1.90 during trading hours on Tuesday, hitting $95.48. 694,227 shares of the stock were exchanged, compared to its average volume of 1,053,051. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. Mirum Pharmaceuticals, Inc. has a 12-month low of $47.15 and a 12-month high of $114.99. The company has a market cap of $5.82 billion, a price-to-earnings ratio of -7.02 and a beta of 0.50. The stock’s 50-day moving average price is $97.53 and its two-hundred day moving average price is $90.70.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million for the quarter, compared to analysts’ expectations of $148.21 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. The firm’s revenue for the quarter was up 43.3% compared to the same quarter last year. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $1,478,000. Candriam S.C.A. lifted its stake in shares of Mirum Pharmaceuticals by 8.0% in the 3rd quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after purchasing an additional 30,021 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $22,041,000. TD Asset Management Inc acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $1,129,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $503,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MIRM. TD Cowen boosted their price objective on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday. HC Wainwright set a $185.00 price objective on Mirum Pharmaceuticals in a research note on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Finally, Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.64.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.